Compare OSRH & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSRH | HCWB |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 14.8M |
| IPO Year | N/A | 2021 |
| Metric | OSRH | HCWB |
|---|---|---|
| Price | $0.36 | $4.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 549.9K | 473.9K |
| Earning Date | 05-19-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | N/A | ★ $4,099,750.00 |
| Revenue This Year | $9.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.25 |
| 52 Week High | $1.24 | $7.35 |
| Indicator | OSRH | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 70.51 |
| Support Level | $0.30 | $0.59 |
| Resistance Level | $0.45 | $4.88 |
| Average True Range (ATR) | 0.03 | 0.34 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 76.69 | 77.05 |
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.